Advances in the diagnosis of latent tuberculosis infection in patients on renal replacement therapy;Avances en el diagnóstico de la infección tuberculosa latente en pacientes en tratamiento renal sustitutivo

Nefrologia

Volumn 31, Issue 2, 2011, Pages 137-141

  Arias Guillen M ^a   Palomar, R ^b   Arias, M ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; DIAGNOSTIC AGENT; GAMMA INTERFERON;

BLOOD; CHRONIC KIDNEY FAILURE; EUROPE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; ISOLATION AND PURIFICATION; KIDNEY TRANSPLANTATION; LABORATORY DIAGNOSIS; LATENT TUBERCULOSIS; MICROBIOLOGY; MIGRATION; MYCOBACTERIUM TUBERCULOSIS; NOTE; POSTOPERATIVE COMPLICATION; PREVALENCE; RENAL REPLACEMENT THERAPY; RISK; SECRETION; SENSITIVITY AND SPECIFICITY; STATISTICS; TUBERCULIN TEST;

ANTIGENS, BACTERIAL; EMIGRANTS AND IMMIGRANTS; EUROPE; FALSE NEGATIVE REACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INCIDENCE; INTERFERON-GAMMA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RENAL REPLACEMENT THERAPY; RISK; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

EID: 79955083892     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Feb.10823     Document Type: Note

References (29)

1. World Health Organization (2008) Global Tuberculosis Control-Surveillance, Planning, Financing. Geneva. www.who.int.
2. Red Nacional de Vigilancia Epidemiológica, Instituto de Salud Carlos III. Enfermedades de declaración obligatoria. Casos notificados por comunidades autónomas. Informe anual España 2009 www.isciii.es.
3. http://www.senefro.com.
4. Winthrop KL, Daley CL. A novel assay for screening patients for latent tuberculosis infection prior to anti-THF therapy. Nature Clin Prac 2008;4(9):456-7.
5. Wauters A, Peetermans WE, Van der Brande P, et al. The value of tuberculin skin testing in hemodialysis patients. Nephrol Dial Transplant 2004;19:433-8.
6. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996;16:183-91.
7. González-Gutiérrez M, De Francisco ALM, Sanz S, et al. Interleukin-2 deficit in hemodialysis patients. Role of prostaglandins. Renal Failure 1992;14(4):563-9.
8. Domínguez J, Ruiz-Manzano J. Prueba de la tuberculina: ¿es la hora del cambio? Arch Bronconeumol 2006;42:47-8.
9. http://www.vidrl.org.au/labsandunits/mrl/tbgold.pdf.
10. http://www.oxfordimmunotec.com/.
11. Horsburgh CR, Jr. Priorities for the treatment of latent tuberculosis nfection in the United States. N Engl J Med 2004;350:2060-7.
12. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000;152:247-63.
13. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-70.
14. Stout JE, Menzies D. Predicting tuberculosis: does the IGRA tell the tale? Am J Respir Crit Care Med 2008;177:1055-7.
15. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2009 2006;28:24-30.
16. Adetifa IM, Lugos MD, Hammond A, et al. Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia. BMC Infect Dis 2007;7:122.
17. Dominguez J, Ruiz-Manzano J, De Souza-Galvao M, et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immuno 2008;15:168-71.
18. Menzies D, Pai M, Comstock G. Meta-analysis: New test for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.
19. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149(3):177-84.
20. Simon TA, Paul S, Wartenberg D, et al. Tuberculosis in hemodialysis patients in New Jersey: a statewide study. Infect Control Hosp Epidemiol 1999;20:607-9.
21. Cengiz K, Seker A. Boosted tuberculin skin testing in hemodialysis patients. Am J Infect Control 2006;34:383-7.
22. Ravi Shankar MS, Aravindan AN, Sohal PM, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005;20:2720-4.
23. Smirnoff M, Patt C, Seckler B, et al. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998;113:25-7.
24. Girndt M, Heisel O, Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant 1999;14:676-82.
25. Muñoz P Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-7.
26. Cavusoglu C, Cicek-Saydam C, Karasu Z, et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant 2002;16:257-61.
27. Ram R, Swarnalatha G, Prasad N, et al. Tuberculosis in renal transplant recipients. Transpl Infect Dis 2007;9:97-101.
28. Krance MB, Fisher MA. Prophylaxis of mycobacterial infections in immunocompromised patients. Am Fam Physician 1996;54:1981-8.
29. Manuel O, Humar A, Preiksaitis J, et al. Comparison of Quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7:2797-801.